Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | STING1 | Q86WV6 | 6/20 | 0.45 |
| ▸ | TYMP | P19971 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.42 |
| ▸ | HPRT1 | P00492 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2294538 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNAALBMAPK1STING1 | |
| SCHEMBL2294535 | 0.84 | ALDH1A1 (0.68) | ALDH1A1LMNAALBMAPK1STING1 | |
| SCHEMBL13769966 | 0.84 | ALDH1A1 (0.78) | ALDH1A1LMNAALBMAPK1STING1 | |
| SCHEMBL24358288 | 0.82 | ALDH1A1 (0.80) | ALDH1A1LMNAALBMAPK1STING1 | |
| SCHEMBL9548834 | 0.82 | ALDH1A1 (0.65) | ALDH1A1LMNAALBMAPK1STING1 | |
| Didanosine SCHEMBL16695885 | 0.81 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1STING1 | |
| Didanosine SCHEMBL16695883 | 0.81 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1STING1 | |
| SCHEMBL21637037 | 0.81 | ALDH1A1 (0.78) | ALDH1A1LMNAALBMAPK1STING1 | |
| SCHEMBL10015776 | 0.81 | PNP (0.48) | ALDH1A1LMNAALBMAPK1STING1 | |
| Didanosine SCHEMBL5021456 | 0.81 | ALDH1A1 (1.00) | ALDH1A1LMNAALBMAPK1STING1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-8110676-B2 | Prodrugs activated by RNA-dependent DNA-polymerases | PROTERA S.R.L. (IT) | 2012-02-07 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | PROTERA S.R.L. (IT) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300215-A1 | Prodrugs Activated by Rna-Dependent Dna-Polymerases | TERT, POLRMT, POLI | ALDH1A1 1552/4885LMNA 801/4885ALB 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.